Neutropenia Treatment Market By Drug Type (G-CSF, GM-CSF, Antibiotics, Antifungal, Antiviral), By Pipeline Analysis (Plinabulin - Phase 2/3, EC-18 - Phase 2, SPI-2012 - Phase 3, rHSA-GCSF 2.4mg - Phase 2, Probio-Fix Inum - Phase 2, Pegteograstim - Phase 2, F-627 - Phase 3, Astragalus polysaccharides 500 mg - Phase 2, Leucostim - Phase 3, myelo001 - Phase 3, Romyelocel-L - Phase 3) - Growth, Future Prospects and Competitive Analysis, 2019-2027
Neutropenia treatment accounted for a market value of US$ 11,279.2 Mn in 2018 and projected to grow at a CAGR of 5.0% during the forecast period from 2019 to 2027. In neutropenia count of neutrophil falls giving rise to compromised immunity further increasing the risk of infection. Neutropenia is observed in almost half cases of cancer patients being treated with chemotherapy but out of them most are suffering from leukaemia. According to medical experts, neutropenia can be a chronic condition because without adequate neutrophils patient become vulnerable to life-threatening infections.
"Strong drug pipeline will assist the significant growth of neutropenia treatment market throughout the forecast period"
Drug pipeline of neutropenia treatment is equipped with several promising drugs in phase III of clinical trials such as SPI-2012 (Spectrum Pharmaceuticals, Inc.), F-627 (Generon (Shanghai) Corporation Ltd.), Leucostim (Dong-A ST Co., Ltd.), myelo001 (Myelo Therapeutics, Inc.), Plinabulin (BeyondSpring Pharmaceuticals Inc.), and Romyelocel-L (Cellerant Therapeutics, Inc.). Neutropenia caused due to several causes major being the post-chemotherapy decrease in count of neutrophils. Increasing prevalence of leukemia expected to rise the neutropenia cases as chemotherapy being the first-line of treatment for leukemia. However, precautionary treatment regimen is ready to avoid effect of neutropenia-based infections with antibacterial, antiviral and antifungal drugs.
"North America dominated the overall global market specifically due to promising drug pipeline, and developed diagnostic landscape"
In 2018, North America dominated the market and expected to retain its position throughout the forecast period due to rising awareness related to neutropenia, increasing prevalence of side effects related to chemotherapy during leukemia treatment, and high expectation from drugs in pipeline. According to several studies, the prevalence of neutropenia is around 4.4% and expected to increase in specific regions with rising prevalence of leukemia. During the forecast period from 2019 to 2027, Asia Pacific will grow gradually due to increasing awareness related to neutropenia diagnosis & treatment coupled with developing diagnostic technologies in rare disease sector.
Historical & Forecast Period
The neutropenia treatment market analyzed considering current market trends for base year 2018 and based on future trends CAGRs calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
This report comprises detailed qualitative and quantitative data related to the neutropenia treatment market along with key factors related to the market such as opportunities, drivers, & restraints. An elaborative data covering market drivers, challenges & opportunities provided explicitly for country-level and regional segmentation. This report covered brief information associated with the global neutropenia treatment market segmented such as drug class type, and geography. The pipeline analysis of neutropenia treatment market comprising drugs under trials in preclinical studies phase I, II & III. Competitive analysis of the major companies is included in neutropenia treatment market along with detailed data related to the competitive landscape of the market and recent strategies & products entering the market.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2017-2027 |
| Base Year | 2018 |
| Forecast Period | 2019-2027 |
| Historical Year | 2017 |
| Unit | USD Million |
| Segmentation |
Type of Drug Class Segment (2017–2027; US$ Mn) |
|
Pipeline Analysis |
|
|
Geography Segment (2017–2027; US$ Mn) |
The key companies included in the neutropenia treatment industry analyzed based on financial data, product portfolio, current press releases, and major market strategies. This report also includes attractive investment proposition studied based on exclusive geographical PESTEL analysis. Major companies included in the report are Amgen, Inc., Spectrum Pharmaceuticals, Inc., Generon (Shanghai) Corporation Ltd., Dong-A ST Co., Ltd., BeyondSpring Pharmaceuticals Inc., Myelo Therapeutics, Inc., Cellerant Therapeutics, Inc., and Sandoz (Subsidiary of Novartis AG) among others.
Key questions answered in this report
- Which is the most frequent drug class to manage & treat neutropenia & Why?
- What are the novel market strategies followed by the major companies & competitive landscape of the neutropenia treatment market?
- Which are the recent and upcoming drugs in neutropenia treatment market?
- Which is the largest and fastest-growing neutropenia treatment segment globally?
- What are the drivers, restraints, & opportunities in the neutropenia treatment market?
- Which are the major geographical markets (regions and countries) of neutropenia treatment market?
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global NT Market Portraiture
2.2. Global NT Market, by Type of Drug Class, 2018 (US$ Mn)
2.3. Global NT Market, by Geography, 2018 Vs 2027 (Value %)
Chapter 3. Global Neutropenia Treatment (NT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018
Chapter 4. Global Neutropenia Treatment (NT) Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Granulocyte-colony stimulating factor (G-CSF)
4.3. Granulocyte-macrophage colony-stimulating factor (GM-CSF)
4.4. Antibiotics
4.5. Antifungal
4.6. Antiviral
Chapter 5. Global Neutropenia Treatment (NT) Market, Pipeline Analysis
5.1. Overview
5.2. Plinabulin - Phase 2/3 (BeyondSpring Pharmaceuticals Inc.)
5.3. EC-18 - Phase 2 (Enzychem Lifesciences Corporation)
5.4. SPI-2012 - Phase 3 (Spectrum Pharmaceuticals, Inc.)
5.5. rHSA-GCSF 2.4mg - Phase 2 (Tianjin SinoBiotech Ltd.)
5.6. Probio-Fix Inum - Phase 2 (S&D Pharma SK s.r.o.)
5.7. Pegteograstim - Phase 2 (Samsung Medical Center)
5.8. F-627 - Phase 3 (Generon (Shanghai) Corporation Ltd.)
5.9. Astragalus polysaccharides 500 mg - Phase 2 (PhytoHealth Corporation)
5.10. Leucostim - Phase 3 (Dong-A ST Co., Ltd.)
5.11. myelo001 - Phase 3 (Myelo Therapeutics, Inc.)
5.12. Romyelocel-L - Phase 3 (Cellerant Therapeutics, Inc.)
Chapter 6. Global Neutropenia Treatment (NT) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America NT Market Analysis, 2017 – 2027
6.2.1. North America NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.2.2. North America NT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe NT Market Analysis, 2017 – 2027
6.3.1. Europe NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.3.2. Europe NT Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific NT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific NT Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America NT Market Analysis, 2017 – 2027
6.5.1. Latin America NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.5.2. Latin America NT Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) NT Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.6.2. MEA NT Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Pfizer, Inc.
7.3. Myelo Therapeutics, Inc.
7.4. Cellerant Therapeutics, Inc.
7.5. Sandoz (Subsidary of Novartis AG)
7.6. BeyondSpring Pharmaceuticals Inc.
7.7. Enzychem Lifesciences Corporation
7.8. Spectrum Pharmaceuticals, Inc.
7.9. Tianjin SinoBiotech Ltd.
7.10. S&D Pharma SK s.r.o.
7.11. Samsung Medical Center
7.12. Generon (Shanghai) Corporation Ltd.
7.13. PhytoHealth Corporation
7.14. Dong-A ST Co., Ltd.
* Here we are using NT as a short form of Neutropenia Treatment
TABLE 1 Global Neutropenia Treatment (NT) Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 2 North America NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 3 North America NT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 4 Europe NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 5 Europe NT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 6 Asia Pacific NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 7 Asia Pacific NT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 8 Latin America NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 9 Latin America NT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Middle East & Africa NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 11 Middle East And Africa NT Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 12 Amgen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Myelo Therapeutics, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Cellerant Therapeutics, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Sandoz (Subsidary of Novartis AG): Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 BeyondSpring Pharmaceuticals Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Enzychem Lifesciences Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Spectrum Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Tianjin SinoBiotech Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 S&D Pharma SK s.r.o. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Samsung Medical Center: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Generon (Shanghai) Corporation Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 PhytoHealth Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Dong-A ST Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
FIG. 1 Neutropenia Treatment (NT): Market Segmentation
FIG. 2 Global NT Market Share, by Type of Drug Class, 2018 (US$ Mn)
FIG. 3 Global NT Market, by Geography, 2018 Vs 2027 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2018
FIG. 5 Market Competition Landscape, by Key Players, 2018
FIG. 6 Global Granulocyte-colony stimulating factor (G-CSF) Market for NT, 2017 – 2027 (US$ Mn)
FIG. 7 Global Granulocyte-macrophage colony-stimulating factor (GM-CSF) Market for NT, 2017 – 2027 (US$ Mn)
FIG. 8 Global Antibiotics Market for NT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Antifungal Market for NT, 2017 – 2027 (US$ Mn)
FIG. 10 Global Antiviral Market for NT, 2017 – 2027 (US$ Mn)
FIG. 11 Global Plinabulin Market for NT, Till 2027 (US$ Mn)
FIG. 12 Global SPI-2012 Market for NT, Till 2027 (US$ Mn)
FIG. 13 Global Leucostim Market for NT, Till 2027 (US$ Mn)
FIG. 14 Global myelo001 Market for NT, Till 2027 (US$ Mn)
FIG. 15 Global Romyelocel-L Market for NT, Till 2027 (US$ Mn)
FIG. 16 U.S. NT Market, 2017 – 2027 (US$ Mn)
FIG. 17 Canada NT Market, 2017 – 2027 (US$ Mn)
FIG. 18 U.K. NT Market, 2017 – 2027 (US$ Mn)
FIG. 19 Germany NT Market, 2017 – 2027 (US$ Mn)
FIG. 20 Rest Of Europe NT Market, 2017 – 2027 (US$ Mn)
FIG. 21 Japan NT Market, 2017 – 2027 (US$ Mn)
FIG. 22 China NT Market, 2017 – 2027 (US$ Mn)
FIG. 23 Rest Of Asia Pacific NT Market, 2017 – 2027 (US$ Mn)
FIG. 24 Brazil NT Market, 2017 – 2027 (US$ Mn)
FIG. 25 Mexico NT Market, 2017 – 2027 (US$ Mn)
FIG. 26 Rest Of Latin America NT Market, 2017 – 2027 (US$ Mn)
FIG. 27 GCC NT Market, 2017 – 2027 (US$ Mn)
FIG. 28 Rest Of Middle East And Africa NT Market, 2017 – 2027 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)